La filariosi da Mansonella perstans

Translated title of the contribution: Mansonella perstans filariasis

E. R. Bregani, F. Tantardini, A. Rovellini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mansonella perstans filariasis is widely present in Africa and equatorial America and its pathogenicity has been recently reconsidered. Although M. perstans infection has been considered a minor filariasis, remaining asymptomatic in most of infected subjects, more recent studies have shown that M. perstans is capable of inducing a variety of clinical features, including angioedemas, swellings like the "Calabar swellings" of loiasis, pruritus, fever, headache, pain in bursae and/or joint synovia, or in serous cavities. It is likely that some of the pathological changes observed are induced by the immune response to the infection. Eosinophilia is present in many cases of infection. Moreover M. perstans filariasis is difficult to be treated. Effective treatment is lacking and there is no consensus on optimal therapeutic approach. The most commonly used drug is diethylcarbamazine (DEC) that is however often ineffective. Although other drugs have been tried (e.g. praziquantel, ivermectin), none has proven to be reliably and rapidly effective. Mebendazole seemed more active than DEC in eliminating the infection, with a comparable rate of overall responses. Thiabendazole evidenced a small, but significant activity against the infection. Combination treatments (DEC plus mebendazole) resulted in a significantly higher activity compared with the single drugs.

Original languageItalian
Pages (from-to)23-26
Number of pages4
JournalParassitologia
Volume49
Issue number1-2
Publication statusPublished - 2007

Fingerprint

Mansonella
Filariasis
Diethylcarbamazine
Mebendazole
Infection
Mansonelliasis
Loiasis
Pharmaceutical Preparations
Thiabendazole
Praziquantel
Angioedema
Ivermectin
Synovial Fluid
Eosinophilia
Pruritus
Headache
Virulence
Consensus
Fever
Therapeutics

ASJC Scopus subject areas

  • Parasitology
  • Immunology and Microbiology(all)

Cite this

La filariosi da Mansonella perstans. / Bregani, E. R.; Tantardini, F.; Rovellini, A.

In: Parassitologia, Vol. 49, No. 1-2, 2007, p. 23-26.

Research output: Contribution to journalArticle

Bregani, ER, Tantardini, F & Rovellini, A 2007, 'La filariosi da Mansonella perstans', Parassitologia, vol. 49, no. 1-2, pp. 23-26.
Bregani, E. R. ; Tantardini, F. ; Rovellini, A. / La filariosi da Mansonella perstans. In: Parassitologia. 2007 ; Vol. 49, No. 1-2. pp. 23-26.
@article{cf1eb32866bc43e3a0c5fad527ebad3e,
title = "La filariosi da Mansonella perstans",
abstract = "Mansonella perstans filariasis is widely present in Africa and equatorial America and its pathogenicity has been recently reconsidered. Although M. perstans infection has been considered a minor filariasis, remaining asymptomatic in most of infected subjects, more recent studies have shown that M. perstans is capable of inducing a variety of clinical features, including angioedemas, swellings like the {"}Calabar swellings{"} of loiasis, pruritus, fever, headache, pain in bursae and/or joint synovia, or in serous cavities. It is likely that some of the pathological changes observed are induced by the immune response to the infection. Eosinophilia is present in many cases of infection. Moreover M. perstans filariasis is difficult to be treated. Effective treatment is lacking and there is no consensus on optimal therapeutic approach. The most commonly used drug is diethylcarbamazine (DEC) that is however often ineffective. Although other drugs have been tried (e.g. praziquantel, ivermectin), none has proven to be reliably and rapidly effective. Mebendazole seemed more active than DEC in eliminating the infection, with a comparable rate of overall responses. Thiabendazole evidenced a small, but significant activity against the infection. Combination treatments (DEC plus mebendazole) resulted in a significantly higher activity compared with the single drugs.",
keywords = "Diethylcarbamazine, Mansonella perstans filariasis, Mansonella perstans treatment, Mebendazole, Thiabendazole",
author = "Bregani, {E. R.} and F. Tantardini and A. Rovellini",
year = "2007",
language = "Italian",
volume = "49",
pages = "23--26",
journal = "Parassitologia",
issn = "0048-2951",
publisher = "Lombardo Editore",
number = "1-2",

}

TY - JOUR

T1 - La filariosi da Mansonella perstans

AU - Bregani, E. R.

AU - Tantardini, F.

AU - Rovellini, A.

PY - 2007

Y1 - 2007

N2 - Mansonella perstans filariasis is widely present in Africa and equatorial America and its pathogenicity has been recently reconsidered. Although M. perstans infection has been considered a minor filariasis, remaining asymptomatic in most of infected subjects, more recent studies have shown that M. perstans is capable of inducing a variety of clinical features, including angioedemas, swellings like the "Calabar swellings" of loiasis, pruritus, fever, headache, pain in bursae and/or joint synovia, or in serous cavities. It is likely that some of the pathological changes observed are induced by the immune response to the infection. Eosinophilia is present in many cases of infection. Moreover M. perstans filariasis is difficult to be treated. Effective treatment is lacking and there is no consensus on optimal therapeutic approach. The most commonly used drug is diethylcarbamazine (DEC) that is however often ineffective. Although other drugs have been tried (e.g. praziquantel, ivermectin), none has proven to be reliably and rapidly effective. Mebendazole seemed more active than DEC in eliminating the infection, with a comparable rate of overall responses. Thiabendazole evidenced a small, but significant activity against the infection. Combination treatments (DEC plus mebendazole) resulted in a significantly higher activity compared with the single drugs.

AB - Mansonella perstans filariasis is widely present in Africa and equatorial America and its pathogenicity has been recently reconsidered. Although M. perstans infection has been considered a minor filariasis, remaining asymptomatic in most of infected subjects, more recent studies have shown that M. perstans is capable of inducing a variety of clinical features, including angioedemas, swellings like the "Calabar swellings" of loiasis, pruritus, fever, headache, pain in bursae and/or joint synovia, or in serous cavities. It is likely that some of the pathological changes observed are induced by the immune response to the infection. Eosinophilia is present in many cases of infection. Moreover M. perstans filariasis is difficult to be treated. Effective treatment is lacking and there is no consensus on optimal therapeutic approach. The most commonly used drug is diethylcarbamazine (DEC) that is however often ineffective. Although other drugs have been tried (e.g. praziquantel, ivermectin), none has proven to be reliably and rapidly effective. Mebendazole seemed more active than DEC in eliminating the infection, with a comparable rate of overall responses. Thiabendazole evidenced a small, but significant activity against the infection. Combination treatments (DEC plus mebendazole) resulted in a significantly higher activity compared with the single drugs.

KW - Diethylcarbamazine

KW - Mansonella perstans filariasis

KW - Mansonella perstans treatment

KW - Mebendazole

KW - Thiabendazole

UR - http://www.scopus.com/inward/record.url?scp=44449141137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449141137&partnerID=8YFLogxK

M3 - Articolo

C2 - 18416002

AN - SCOPUS:44449141137

VL - 49

SP - 23

EP - 26

JO - Parassitologia

JF - Parassitologia

SN - 0048-2951

IS - 1-2

ER -